PEB - Pacific Edge

[System]

Pacific Edge Limited is a cancer diagnostics company specialising in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.

Pacific Edge's products are built from their proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.

Their intellectual property covers the areas of bladder, gastric, colorectal and endometrial cancers and melanoma; however, their commercial focus is on bladder cancer products for the short to medium term. The Company's wider portfolio is expected to provide them with further options in the future.

It is anticipated that PEB will list on the ASX during September 2021.

Home | Pacific Edge

Innovative solutions for cancer diagnostics.

www.pacificedgedx.com

 

[Dona Ferentes]

Pacific Edge is listed on the NZX Main Board and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited

Market cap is about NZ$1Billion

The ASX listing is pro forma

Listing date	23 September 2021 #
Company contact details	https://www.pacificedgedx.com/ Ph: +64 3 479 5800
Principal Activities	Development and deployment of specialist cancer diagnostics tools
GICS industry group	TBA
Issue Price	N/A
Issue Type	Ordinary Fully Paid Shares
Security code	PEB

 

[Dona Ferentes]

The ASX listing of NZ biotech Pacifc Edge (PEB) occurred at 11am today.... opened at $1.55 and holding around that price.

 

[Dona Ferentes]

In the cap raise held at the same time as ASX listing, PEB has added 59,259,259 new shares ; Issue price per security NZ$1.35 or A$1.31. This is an additional 8.13% of share base.

There is also a Retail Offer just open, to raise up to a further NZ$20 million (A$19.4 million) (with ability to accept oversubscriptions). Each Eligible Shareholder will be entitled to apply for up to NZ$50,000 of new shares under the Retail Offer.

SP trading a bit above, still, at $1.43

 

[Dona Ferentes]

and .... one to avoid

Bell Potter finally initiated research coverage, with a speculative buy recommendation at a 12-month price target of $1.10 a share.

Which is a 35 per cent increase on the prevailing market price of 88c Gee, thanks guys. Why, 6 months ago, there was an...

$80 million equity raising ahead of a dual listing on the Australian Securities Exchange at $1.31.

The company had stockbrokers Bell Potter, Jarden and Forsyth Barr launch the deal

 

[Dona Ferentes]

and .... one to avoid
.......

watch out below.

Pacific Edge’s chief executive, Peter Meintjes, told investors he was “surprised” and “disappointed” after a US Medicare administrator, Novitas, determined the oncology product was “not considered medically reasonable and necessary”.

Mr Meintjes said the rejection appeared to “materially misunderstand” the role its Cxbladder tool plays in bladder cancer diagnostics.

This reduced the diagnostic group’s market value to $NZ97.3 million from $NZ401.1 million. Its ASX-listed scrip plunged 72.4 per cent to 10.5¢ from 38¢.

“Now that Novitas has codified their views in a finalised local determination coverage, we are able to consider and assess the potential necessary adjustments required to regain Medicare coverage,” chief medical officer Tamer Aboushwareb said.

... yeah, mebe.

Since listing ....

 

[Dona Ferentes]

Pacific Edge has warned that proposed changes to US Food and Drug Administration guidelines could result in more red tape for its bladder cancer diagnostic device, Cxbladder.

 

[divs4ever]

Pacific Edge has warned that proposed changes to US Food and Drug Administration guidelines could result in more red tape for its bladder cancer diagnostic device, Cxbladder.

and that is why i avoid this sector , the FDA is a beast in it's own class

so i am guessing this test actually works in some cases ..

 

[Dona Ferentes]

from 10c to 16c since this news of last week:

Pacific Edge today notes the American Urological Association is seeking urologist feedback on a draft standard of care guideline for the evaluation of microhematuria. The consultation is taking place under strict conditions of non-disclosure with the process commencing after 15 September 2024.

Pacific Edge also notes the Centers for Medicare & Medicaid Services (CMS) has indicated - through a meeting with stakeholders that included The Coalition for 21st Century Medicine - that it had agreed to an extension to deliberations on the draft Local Coverage Determination ‘Genetic Testing for Oncology’ (DL 39365) to ensure Pacific Edge’s Medicare Administrative Contractor, Novitas, had time to respond to a large volume of detailed comments and because the LCD raises unique issues. Novitas confirmed it had been granted )an extension to finalize, retire or start over on the draft LCD in late July.